Diosmin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Diosmin: From Chronic Venous Disease (Inferred) to Amenorrhea
One-Sentence Summary
Diosmin is a venoactive flavonoid that is marketed in Singapore as an oral tablet. The registration records compiled for this report do not state an approved indication. The TxGNN model predicts it may be effective for amenorrhea, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration records (diosmin is generally used for venous insufficiency) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, diosmin is a venoactive flavonoid used to support vascular tone, venous and lymphatic function, and to reduce inflammation and oxidative stress.
Amenorrhea is a condition of the endocrine and reproductive axis. There is no evident mechanistic path from diosmin's vascular and anti-inflammatory effects to the restoration of menstruation. The high TxGNN score most likely reflects network proximity in the knowledge graph rather than a real pharmacological link, so the prediction should be treated as a probable artifact until tested.
Other predictions for this drug (for example, platelet disorders, coagulation factor deficiencies, Paget disease of bone and esophageal malformation) are also not supported by a plausible mechanism. The one with a partial indirect link is thrombophilia, discussed below.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for amenorrhea.
For reference, the seventh-ranked prediction, thrombophilia (score 92.94%, evidence level L4), returned two papers. Neither tests diosmin for thrombophilia:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33496999 | 2021 | Cohort | Dermatologic Therapy | Single-centre series of 75 Brazilian patients with livedoid vasculopathy, a thrombo-occlusive skin condition; describes clinical, histopathological and treatment data |
| 24214586 | 2013 | Observational | Georgian Medical News | Preeclamptic women had thrombophilia with increased platelet aggregation; fetal heart rate variability was altered |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17191P | Vessosmin Film Coated Tablet 500mg | Tablet, film coated | Not stated |
| SIN16068P | Ruventin Film Coated Tablet 500mg | Tablet, film coated | Not stated |
| SIN01067P | Daflon Tablet 500 mg | Tablet, sugar coated | Not stated |
| SIN15669P | Daflon Film-Coated Tablet 1000 mg | Tablet, film coated | Not stated |
| SIN16960P | Davmorid Film Coated Tablet | Tablet, film coated | Not stated |
A sixth registration, Diosper Film Coated Tablet (SIN11942P), is also valid. All six are single-ingredient oral products.
Safety Considerations
Please refer to the package insert for safety information. No interaction records were found for diosmin in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The amenorrhea prediction has no supporting trials or literature, and no plausible mechanism connects a venoactive flavonoid to an endocrine and reproductive condition. The high model score alone is not enough to justify further investment.
To proceed, the following is needed:
- Mechanism of action data for diosmin, to test any link to reproductive endocrine pathways
- Package insert warnings and contraindications from the Singapore regulator, to complete the safety screening
- The approved indication text for the Singapore registrations
- Any preclinical or clinical evidence on diosmin in amenorrhea, which does not exist in the compiled data
- If a lead is wanted, a focused literature review of thrombophilia, the only prediction with an indirect link, though it also lacks direct evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.